CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 72 enrolled
Drug / intervention
LY3025876 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01870297
NCT01870297Phase 1Completed
CompareCT.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3025876 in Patients With Type 2 Diabetes Mellitus

Eli Lilly and Company·interventional·Posted Jun 6, 2013·Updated Jan 24, 2019

In Brief

A Phase 1 clinical trial evaluating LY3025876, Placebo, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 72 participants across 4 sites.

Detailed Summary

The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 6, 2013
Enrollment StartJun 1, 2013
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.1 years ago

Interventions

LY3025876drug

Administered SQ

Placebodrug

Administered SQ

Liraglutidedrug

Administered SQ